| Literature DB >> 35646994 |
Meng Wang1, Wei Liu2, Ziman Xiong3, Zhen Li3, Jiansha Li4, Xin Xu2, Meng Zhang2, Mingyou Xing2, Qin Ning2, Di Wu2, Junying Qi2.
Abstract
Parasitic co-infection is commonly observed in natural populations, yet rare in the laboratory. Multiparasitism can have negative effects on the host, ranging from the atypical manifestations to increased mortality, consequently, it may be misdiagnosed and treated with unsuitable anthelmintic medicines. Therefore, reliable diagnosis is critical for appropriate treatment of parasitic co-infection. Herein, we report a case of a 31-year-old woman with persistent eosinophilia and hypoechoic liver lesion on ultrasound. The microscopic examination of multiple stool specimens did not find any pathogens. The patient had serum specific anti-Trichinella IgG antibody by Dot enzyme-linked immunosorbent assay (Dot-ELISA). After treatment with albendazole, contrast-enhanced magnetic resonance imaging (MRI) revealed more lesions in the liver. Subsequently, liver biopsy was performed in this patient and Fasciola hepatica was identified using metagenomic next-generation sequencing (mNGS) as well as polymerase chain reaction. After treatment with triclabendazole, which is the only anthelmintic drug specifically available against this fluke, her eosinophil count returned normal, and the liver lesions were significantly regressed. This case highlights the diagnostic challenge posed by parasitic co-infection, which merits more in-depth evaluation to confirm the diagnosis.Entities:
Keywords: Fasciola hepatica; Trichinella spiralis; case report; magnetic resonance imaging (MRI); metagenomic next-generation sequencing (mNGS)
Year: 2022 PMID: 35646994 PMCID: PMC9132012 DOI: 10.3389/fmed.2022.881356
Source DB: PubMed Journal: Front Med (Lausanne) ISSN: 2296-858X
Figure 1(A) The liver MRI image. There are several typical curved tunnel signs (red arrows and dotted frame) on T2WI. (B) A serial image of the patient before and after anti-helminthic therapy in the hepatic anterior lobe. The image on March 30th, 2021, showed typical “curved tunnel” signs in hepatic right anterior and posterior lobe on T1WI and T2WI image (red dotted frames and arrows). On April 17th, a month after the first therapy, the area of curved tunnel signs in hepatic anterior lobe decreased. After the following anti-helminthic treatments, the liver MRI image showed further decreased signs (29/7/2021). (C) A serial image showed dynastic change in the hepatic posterior lobe. On the image of March 30th, there were several curved tunnels in the marked yellow dotted frame. The new massive patchy slight hyperintense signals on April 17th were almost gone on the image of July 29th. Besides, we observed newly tunnel changes located under the subcapsular (orange arrows). (D) Coronal image showed subcapsular lesion appeared first on the image of May 18th, 2021. During the anti-helminthic therapy course, the lesion expanded and was progressed into abscess. (E) On the T1 contrast enhanced MR image, the subcapsular lesion in hepatic right lobe decreased significantly (red arrows).
Figure 2HE staining (400X) showed massive eosinophilic infiltration and abscess formation. The dashed white box indicates abscesses and the yellow arrow indicates eosinophilic infiltration.
Figure 3(A) The mNGS result. 1,299 specific Fasciola hepatica sequences that covered 0.0042% of the total Fasciola hepatica genome were detected by mNGS in the hepatic sample of the patient. The sequences were symmetrical matched with the median depth. (B,C) Fasciola Hepatica and Trichinella spiralis identification of gene amplification.
Figure 4The dynamic changes of serological markers. (A–D) Eosinophil counts and percentages before and after every therapy (each therapy course: 3.18–3.24/4.15-4.20/5.14–5.22/6.14–6.23/8.30–9.6/9.15–9.20/10.1–10.5). The number of Eosinophil decreased after four therapies (June 23th). The count of Eosinophil showed a transient and significant increase on the measurement of July 29th, then kept within low level. (E) The trend of other markers. The level of IgE kept increasing and tripled compared with the first measurement. After four therapies, the level of IgE gradually went down. ALT, AST, albumin, and globulin kept within normal range.